# Competitive Pipeline Brief — Johnson & Johnson

## Provenance
- Run date (UTC): 2026-01-08
- Source URL: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Stored source PDF: `sources/jnj/2026-01-08.pdf`
- Source SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`
- Extracted 'as of' date: Unknown

## Executive summary
**Johnson & Johnson Undergoes Significant Pipeline Streamlining and Advancement**

Johnson & Johnson's latest pipeline update showcases a substantial restructuring, with over 80 assets and indications removed from the development roadmap. This extensive change predominantly reflects the successful advancement and commercialization of key assets, including new indications or formulations for established blockbusters such as CARVYKTI, DARZALEX, RYBREVANT, AKEEGA, and ERLEADA, particularly bolstering the oncology franchise. Additionally, several late-stage programs in immunology (e.g., nipocalimab, TREMFYA, STELARA) and neuroscience (e.g., CAPLYTA, SPRAVATO) appear to have transitioned from the development pipeline, likely due to regulatory approvals or completion of pivotal trials. Concurrently, a notable number of earlier-stage, wholly-owned 'JNJ-' numbered candidates across various therapeutic areas have also been removed, suggesting a strategic pruning to enhance R&D efficiency and reallocate resources towards programs with higher strategic conviction.

### Why it matters
- Reinforces J&J's strong execution in advancing late-stage assets through clinical development to regulatory approval and market, particularly in high-value therapeutic areas.
- Indicates potential for sustained revenue growth and market share expansion from recently approved indications and formulations, especially within the oncology and immunology segments.
- Suggests a more disciplined and focused R&D approach, potentially freeing up resources for higher-priority internal programs, external innovation, or strategic acquisitions.
- May create pipeline gaps in certain early-stage therapeutic areas, necessitating a clear strategy for replenishment through internal discovery or business development.
- Highlights the company's commitment to optimizing its portfolio, allowing for a concentrated effort on programs with the greatest potential for patient impact and commercial success.

### Watchlist
- Monitor commercial performance and market uptake of recently launched or expanded products, especially in multiple myeloma (CARVYKTI, TALVEY, TECVAYLI) and prostate cancer (AKEEGA, ERLEADA).
- Watch for official company announcements or investor presentations that provide further clarity on the rationale for specific early-stage asset removals.
- Assess future pipeline updates for new entries or strategic acquisitions that signal J&J's strategy to replenish and diversify its R&D portfolio.
- Analyze Q3/Q4 earnings call transcripts for executive commentary on updated R&D strategy, pipeline priorities, and potential resource reallocation.
- Keep an eye on competitive landscape developments in therapeutic areas where J&J has pruned its early-stage pipeline, identifying potential emerging threats or opportunities.

## Pipeline snapshot (counts by phase)
_No programs extracted._

## Change log (previous vs current)
- Confidence score (0–1): 0.55

### New / Added items
_None detected._

### Removed / Discontinued items
- **AKEEGA (niraparib/abiraterone)** — M1 Metastatic Castration-Sensitive Prostate Cancer
- **Bleximenib** — Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine
- **Bleximenib** — Relapsed Refractory Acute Myeloid Leukemia
- **CABENUVA** — HIV Adolescents
- **CAPLYTA (lumateperone)** — Adjunctive Treatment for Major Depressive Disorder
- **CAPLYTA (lumateperone)** — Bipolar Mania
- **CAPLYTA (lumateperone)** — Pediatric Psychiatric Indications
- **CARVYKTI (Ciltacabtagene autoleucel)** — Frontline Multiple Myeloma TNI
- **CARVYKTI (Ciltacabtagene autoleucel)** — Frontline Multiple Myeloma Transplant Eligible vs ASCT
- **DARZALEX (daratumumab)** — Frontline multiple myeloma transplant ineligible
- **DARZALEX (daratumumab)** — Smoldering Multiple Myeloma
- **ERLEADA (apalutamide)** — High Risk Prostate Cancer
- **ERLEADA (apalutamide)** — Localized Prostate Cancer
- **icotrokinra** — Psoriasis
- **icotrokinra** — Psoriatic Arthritis
- **icotrokinra** — Ulcerative Colitis
- **IMAAVY (nipocalimab)** — Generalized Myasthenia Gravis
- **IMAAVY (nipocalimab)** — Generalized Myasthenia Gravis Pediatrics
- **IMBRUVICA (ibrutinib)** — Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)
- **IMBRUVICA (ibrutinib)** — Frontline Mantle Cell Lymphoma
- **INLEXZO (gemcitabine intravesical system)** — High Risk Non Muscle Invasive Bladder Cancer BGC Experienced
- **INLEXZO (gemcitabine intravesical system)** — Non Muscle Invasive Bladder Cancer
- **INLEXZO (gemcitabine intravesical system)** — Non Muscle Invasive Bladder Cancer BCG-naïve High Risk
- **ITI-1284** — Alzheimer's Disease-Related Agitation
- **ITI-1284** — Alzheimer's Disease-Related Psychosis
- **ITI-1284** — Generalized Anxiety Disorder
- **JNJ-0387** — Solid Tumors
- **JNJ-0631 (ARX305)** — Renal Cancer
- **JNJ-0683 (ARX788)** — Breast Cancer
- **JNJ-1493** — Hematological Malignancies
- **JNJ-1887 sCD59** — Geographic Atrophy
- **JNJ-1900 (NBTXR3)** — Head and Neck Cancer
- **JNJ-1900 (NBTXR3)** — Lung Cancer
- **JNJ-2056 (tau active immunotherapy)** — Alzheimer's Disease
- **JNJ-2638** — Gastrointestinal Cancer
- **JNJ-2761** — Multiple Myeloma
- **JNJ-3413** — Lymphoma
- **JNJ-4496** — Hematological Malignancies
- **JNJ-4680** — Lung Cancer
- **JNJ-4681** — Hematological Malignancies
- **JNJ-4804 Co-antibody Therapy** — Crohn's Disease
- **JNJ-4804 Co-antibody Therapy** — Psoriatic Arthritis
- **JNJ-4804 Co-antibody Therapy** — Ulcerative Colitis
- **JNJ-4916** — Lung Cancer
- **JNJ-5108** — Immunological Diseases
- **JNJ-5120** — Major Depressive Disorder
- **JNJ-5322** — Multiple Myeloma
- **JNJ-5939** — Atopic Dermatitis
- **JNJ-6420** — Prostate Cancer
- **JNJ-6848** — Immunological Diseases
- **JNJ-7446** — Lung Cancer
- **JNJ-7528** — Atopic Dermatitis
- **JNJ-8177 (ARX517)** — Prostate Cancer
- **JNJ-8377** — Lymphoma
- **JNJ-8543** — Hematological Malignancies
- **JNJ-9401** — Prostate Cancer
- **JNJ-9530** — Hematological Malignancies
- **JNJ-9892** — Hematological Malignancies
- **JNJ-9968** — Hematological Malignancies
- **macitentan** — Pulmonary Arterial Hypertension 75mg
- **milvexian (Factor Xla)** — Acute Coronary Syndrome
- **milvexian (Factor Xla)** — Atrial Fibrillation
- **milvexian (Factor Xla)** — Secondary Stroke Prevention
- **nipocalimab** — Chronic Inflammatory Demyelinating Polyneuropathy
- **nipocalimab** — Fetal and Neonatal Alloimmune Thrombocytopenia
- **nipocalimab** — Hemolytic Disease of the Fetus and Newborn
- **nipocalimab** — Idiopathic Inflammatory Myopathy
- **nipocalimab** — Sjogren's Disease
- **nipocalimab** — Systemic Lupus Erythematosus
- **nipocalimab** — Warm Autoimmune Hemolytic Anemia
- **pasritamig** — Prostate Cancer
- **posdinemab** — Alzheimer's Disease
- **RPGR Gene Therapy** — Retinitis Pigmentosa
- **RYBREVANT (amivantamab)**
- **RYBREVANT (amivantamab)** — Colorectal Cancer
- **RYBREVANT (amivantamab)** — Colorectal Cancer 2L
- **RYBREVANT (amivantamab)** — Frontline Non Small Cell Lung Cancer in combination with chemotherapy
- **seltorexant** — Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms
- **SIMPONI (golimumab)** — Pediatric Ulcerative Colitis
- **SIRTURO** — Leprosy
- **SIRTURO** — Tuberculosis Long Acting
- **SPRAVATO (esketamine)** — Major Depressive Disorder with Suicidal Ideation Pediatrics
- **SPRAVATO (esketamine)** — Treatment Resistant Depression monotherapy
- **STELARA (ustekinumab)** — Pediatric Crohn's Disease
- **STELARA (ustekinumab)** — Pediatric Ulcerative Colitis
- **TALVEY (talquetamab)** — Relapsed Refractory Multiple Myeloma A-CD38 Naïve
- **TALVEY (talquetamab)** — Relapsed Refractory Multiple Myeloma CD38 exposed
- **TALVEY + TECVAYLI** — Relapsed Refractory Multiple Myeloma
- **TALVEY + TECVAYLI** — Relapsed Refractory Multiple Myeloma CD38 exposed
- **TALVEY + TECVAYLI** — TIE NDMM in combination with DR
- **TAR-210 (RIS/erdafitinib)** — Intravesical Delivery System for Localized Bladder Cancer
- **TECVAYLI (teclistamab)** — Multiple Myeloma 1-3PLs
- **TECVAYLI (teclistamab)** — Relapsed Refractory Multiple Myeloma CD38 exposed
- **TECVAYLI (teclistamab)** — TE NDMM maintenance
- **TECVAYLI (teclistamab)** — TIE NDMM in combination with DR
- **TREMFYA (guselkumab)** — Pediatric Juvenile Psoriatic Arthritis
- **TREMFYA (guselkumab)** — Pediatric Psoriasis
- **TREMFYA (guselkumab)** — Pediatric Ulcerative Colitis
- **TREMFYA (guselkumab)** — Psoriatic Arthritis Structural Damage
- **TREMFYA (guselkumab)** — Ulcerative Colitis Subcutaneous Induction
- **UPTRAVI (selexipag)** — Pediatric Pulmonary Arterial Hypertension

### Phase changes
_None detected._

## Appendix: extracted programs (first 20)
_No programs extracted._
